Project Grant R43HL128670

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...

Grant Award Summary Analytical Diagnostic Solutions Inc. received a $305,352 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 1, 2025, through June 30, 2026. The company is developing HCY NOW, a quantitative point-of-care device for home-based monitoring of total blood homocysteine (THCy) levels to improve management of homocystinurias (HCUs)—inherited metabolic disorders characterized by plasma homocysteine accumulation. The...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

The Ohio State University received a $765,931 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 22, 2025, with completion targeted for July 31, 2030. The grant supports PF-GUIDE (Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults with Sickle Cell Disease), a multi-center hybrid type I effectiveness-implementation trial designed to deliver evidence-based clinical...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...

This Phase 2 clinical trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), investigates intravenous L-citrulline as an adjunctive therapy to reduce opioid use and hospital length of stay in sickle cell disease patients experiencing vaso-occlusive crises (VOC). The randomized, double-blind, placebo-controlled study will enroll sickle cell patients and assess whether citrulline supplementation—which enhances nitric...

The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award for $997,142 aims to develop a rapid phenylalanine blood level monitor for patients with phenylketonuria (PKU), a lifelong genetic disorder. The product consists of a test strip and device that can provide frequent, accessible monitoring of phenylalanine levels from a finger prick to improve disease management and patient outcomes. The project focuses on optimizing the...

Federal Project Grant Award Summary New Health Sciences, Inc. (operating as Hemanext Inc.) received a $1.02 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 5, 2025, with a completion date of August 31, 2028. The award funds a clinical efficacy trial assessing hypoxic red blood cell (HRBC) transfusions processed through Hemanext's proprietary HemaNEXT ONE system compared to...

This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $412,250.00 to Arizona State University (ASU) to develop a real-time, automated smart catheter analyzer that can detect sepsis through continuous monitoring of urine biomarkers. The goal is to enable earlier diagnosis of sepsis, a life-threatening condition, within minutes rather than hours. This would allow clinicians to quickly intervene and support heart and lung...